Funder
Sanofi K.K.
Bristol-Myers Squibb
Janssen Japan
Meiji Seika Pharma
Ono Pharmaceutical
AbbVie
Takeda Pharmaceutical Company
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Paper: A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple : Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform [Internet]. [cited 2023 Mar 10]. https://ash.confex.com/ash/2020/webprogram/Paper137021.html
2. D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (r2-iss) for overall survival in multiple myeloma: a european myeloma network (emn) report within the harmony project. J Clin Oncol. 2022;40(29):3406–18.
3. Shah GL, Landau H, Londono D, Devlin SM, Kosuri S, Lesokhin AM, et al. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk Lymphoma. 2017;58(8):1823–31.
4. Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019;9(12):94.
5. Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4(15):3509–19.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献